全基因组关联研究荟萃分析识别女性循环抗苗勒管激素水平的三个新位点
该研究通过全基因组关联研究荟萃分析,合并既往AMH GWAS汇总统计量与三个队列中3705名女性的数据,共纳入7049名欧洲裔绝经前女性,在P<5×10-8水平识别出四个与循环AMH水平相关的位点:已知的MCM8位点及AMH、TEX41和CDCA7附近三个新信号。
要点
- 共识别四个与AMH水平相关的位点:MCM8及AMH、TEX41、CDCA7附近三个新信号。
- 最强信号为AMH基因错义变异rs10417628。
- AMH水平与绝经年龄的单核苷酸多态性呈强正相关(rg=0.82,FDR=0.003)。
核心结论
- 在7049名欧洲裔绝经前女性中识别出四个与循环AMH水平相关的位点,包括已知MCM8位点及AMH、TEX41和CDCA7附近三个新信号。
- 探索性两样本孟德尔随机化分析不支持AMH对乳腺癌或多囊卵巢综合征风险有因果效应,但应谨慎解读,因可能把握度不足且遗传工具变量有效性未能充分探索。
研究设计与样本
- 全基因组关联研究荟萃分析,合并既往AMH GWAS汇总统计量与三个队列中3705名新增女性的GWAS数据。
- 共纳入7049名欧洲裔绝经前女性,各队列研究对象中位年龄范围为15.3至48岁。
- 循环AMH水平采用不同ELISA试剂盒在血清或血浆样本中测定,研究特异性分析校正采血年龄和人群分层,汇总统计量采用标准误加权法进行荟萃分析。
- 对达到全基因组显著性(P<5×10-8)的GWAS变异进行功能注释,并开展基于基因的GWAS、通路分析、连锁不平衡得分回归和孟德尔随机化分析。
主要发现
- 在P<5×10-8水平识别出四个与AMH水平相关的位点:既往报道的MCM8位点及AMH、TEX41和CDCA7基因内或附近三个新信号。
- 最强信号为AMH基因错义变异rs10417628。
- 其他三个识别位点的大多数优先基因涉及细胞周期调控。
- 遗传相关分析显示AMH水平与绝经年龄的单核苷酸多态性呈强正相关(rg=0.82,FDR=0.003)。
- 探索性两样本孟德尔随机化分析不支持AMH对乳腺癌或多囊卵巢综合征风险有因果效应。
关键数值与推荐
- 全基因组显著性阈值定义为P<5×10-8。
- AMH水平与绝经年龄的单核苷酸多态性遗传相关系数rg=0.82,FDR=0.003。
临床怎么用
- 作者认为,MCM8、TEX41和CDCA7位点映射的基因参与细胞周期及DNA复制和凋亡等过程,其与AMH关联的机制可能影响卵巢卵泡池大小。
- 作者认为,结果增进了对AMH生物学及卵巢衰老相关生物学过程的认识。
- 作者指出,需随访研究探究AMH基因信号是否由特定检测方法导致的AMH检测减少而非实际循环AMH水平降低所引起。
局限性
- 尽管本研究将最近一次GWAS的样本量翻倍,统计把握度仍相对较低。
- 可能仍缺乏把握度来识别更多AMH遗传变异及确定AMH对乳腺癌等的因果效应。
- 需随访研究探究AMH基因信号是否由特定检测方法导致的AMH检测减少而非实际循环AMH水平降低所引起。
- 探索性两样本孟德尔随机化分析可能把握度不足,且遗传工具变量的有效性未能充分探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Can additional genetic variants for circulating anti-Müllerian hormone (AMH) levels be identified through a genome-wide association study (GWAS) meta-analysis including a large sample of premenopausal women? SUMMARY ANSWER: We identified four loci associated with AMH levels at P < 5 × 10-8: the previously reported MCM8 locus and three novel signals in or near AMH, TEX41 and CDCA7. WHAT IS KNOWN ALREADY: AMH is expressed by antral stage ovarian follicles in women, and variation in age-specific circulating AMH levels has been associated with disease outcomes. However, the physiological mechanisms underlying these AMH-disease associations are largely unknown. STUDY DESIGN, SIZE, DURATION: We performed a GWAS meta-analysis in which we combined summary statistics of a previous AMH GWAS with GWAS data from 3705 additional women from three different cohorts. PARTICIPANTS/MATERIALS, SETTING, METHODS: In total, we included data from 7049 premenopausal female participants of European ancestry. The median age of study participants ranged from 15.3 to 48 years across cohorts. Circulating AMH levels were measured in either serum or plasma samples using different ELISA assays. Study-specific analyses were adjusted for age at blood collection and population stratification, and summary statistics were meta-analysed using a standard error-weighted approach. Subsequently, we functionally annotated GWAS variants that reached genome-wide significance (P < 5 × 10-8). We also performed a gene-based GWAS, pathway analysis and linkage disequilibrium score regression and Mendelian randomization (MR) analyses. MAIN RESULTS AND THE ROLE OF CHANCE: We identified four loci associated with AMH levels at P < 5 × 10-8: the previously reported MCM8 locus and three novel signals in or near AMH, TEX41 and CDCA7. The strongest signal was a missense variant in the AMH gene (rs10417628). Most prioritized genes at the other three identified loci were involved in cell cycle regulation. Genetic correlation analyses indicated a strong positive correlation among single nucleotide polymorphisms for AMH levels and for age at menopause (rg = 0.82, FDR = 0.003). Exploratory two-sample MR analyses did not support causal effects of AMH on breast cancer or polycystic ovary syndrome risk, but should be interpreted with caution as they may be underpowered and the validity of genetic instruments could not be extensively explored. LARGE SCALE DATA: The full AMH GWAS summary statistics will made available after publication through the GWAS catalog (https://www.ebi.ac.uk/gwas/). LIMITATIONS, REASONS FOR CAUTION: Whilst this study doubled the sample size of the most recent GWAS, the statistical power is still relatively low. As a result, we may still lack power to identify more genetic variants for AMH and to determine causal effects of AMH on, for example, breast cancer. Also, follow-up studies are needed to investigate whether the signal for the AMH gene is caused by reduced AMH detection by certain assays instead of actual lower circulating AMH levels. WIDER IMPLICATIONS OF THE FINDINGS: Genes mapped to the MCM8, TEX41 and CDCA7 loci are involved in the cell cycle and processes such as DNA replication and apoptosis. The mechanism underlying their associations with AMH may affect the size of the ovarian follicle pool. Altogether, our results provide more insight into the biology of AMH and, accordingly, the biological processes involved in ovarian ageing. STUDY FUNDING/COMPETING INTEREST(S): Nurses' Health Study and Nurses' Health Study II were supported by research grants from the National Institutes of Health (CA172726, CA186107, CA50385, CA87969, CA49449, CA67262, CA178949). The UK Medical Research Council and Wellcome (217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. This publication is the work of the listed authors, who will serve as guarantors for the contents of this article. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf). Funding for the collection of genotype and phenotype data used here was provided by the British Heart Foundation (SP/07/008/24066), Wellcome (WT092830M and WT08806) and UK Medical Research Council (G1001357). M.C.B., A.L.G.S. and D.A.L. work in a unit that is funded by the University of Bristol and UK Medical Research Council (MC_UU_00011/6). M.C.B.'s contribution to this work was funded by a UK Medical Research Council Skills Development Fellowship (MR/P014054/1) and D.A.L. is a National Institute of Health Research Senior Investigator (NF-0616-10102). A.L.G.S. was supported by the study of Dynamic longitudinal exposome trajectories in cardiovascular and metabolic non-communicable diseases (H2020-SC1-2019-Single-Stage-RTD, project ID 874739). The Doetinchem Cohort Study was financially supported by the Ministry of Health, Welfare and Sports of the Netherlands. The funder had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Ansh Labs performed the AMH measurements for the Doetinchem Cohort Study free of charge. Ansh Labs was not involved in the data analysis, interpretation or reporting, nor was it financially involved in any aspect of the study. R.M.G.V. was funded by the Honours Track of MSc Epidemiology, University Medical Center Utrecht with a grant from the Netherlands Organization for Scientific Research (NWO) (022.005.021). The Study of Women's Health Across the Nation (SWAN) has grant support from the National Institutes of Health (NIH), DHHS, through the National Institute on Aging (NIA), the National Institute of Nursing Research (NINR) and the NIH Office of Research on Women's Health (ORWH) (U01NR004061; U01AG012505, U01AG012535, U01AG012531, U01AG012539, U01AG012546, U01AG012553, U01AG012554, U01AG012495). The SWAN Genomic Analyses and SWAN Legacy have grant support from the NIA (U01AG017719). The Generations Study was funded by Breast Cancer Now and the Institute of Cancer Research (ICR). The ICR acknowledges NHS funding to the NIHR Biomedical Research Centre. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent official views of the funders. The Sister Study was funded by the Intramural Research Program of the National Institutes of Health (NIH), National Institute of Environmental Health Sciences (Z01-ES044005 to D.P.S.); the AMH assays were supported by the Avon Foundation (02-2012-065 to H.B. Nichols and D.P.S.). The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the 'Ministère de l'Économie, de la Science et de l'Innovation du Québec' through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al. (Nature, 2017). F.J.M.B. has received fees and grant support from Merck Serono and Ferring BV. D.A.L. has received financial support from several national and international government and charitable funders as well as from Medtronic Ltd and Roche Diagnostics for research that is unrelated to this study. N.S. is scientific consultant for Ansh Laboratories. The other authors declare no competing interests.
引用
- Verdiesen RMG, van der Schouw YT, van Gils CH, et al. Genome-wide association study meta-analysis identifies three novel loci for circulating anti-Müllerian hormone levels in women. Hum Reprod. 2022. PMID: 35274129. doi:10.1093/humrep/deac028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。